Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

MLYS

Mineralys Therapeutics (MLYS)

Mineralys Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:MLYS
DateTimeSourceHeadlineSymbolCompany
02/14/20255:03AMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:MLYSMineralys Therapeutics Inc
02/12/20256:07AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLYSMineralys Therapeutics Inc
02/12/20256:00AMGlobeNewswire Inc.Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateNASDAQ:MLYSMineralys Therapeutics Inc
02/05/20253:05PMGlobeNewswire Inc.Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025NASDAQ:MLYSMineralys Therapeutics Inc
02/04/20257:05AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLYSMineralys Therapeutics Inc
02/04/20257:00AMGlobeNewswire Inc.Mineralys Therapeutics Completes Enrollment in Explore-CKD Phase 2 Trial of Lorundrostat for the Treatment of Hypertension in Subjects with Stage 2 to 3b CKD and AlbuminuriaNASDAQ:MLYSMineralys Therapeutics Inc
01/08/20257:07AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLYSMineralys Therapeutics Inc
01/08/20257:00AMGlobeNewswire Inc.Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with HypertensionNASDAQ:MLYSMineralys Therapeutics Inc
11/13/20243:27PMEdgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:MLYSMineralys Therapeutics Inc
11/12/20243:04PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:MLYSMineralys Therapeutics Inc
11/12/20247:36AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MLYSMineralys Therapeutics Inc
11/12/20247:32AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLYSMineralys Therapeutics Inc
11/11/20243:05PMGlobeNewswire Inc.Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:MLYSMineralys Therapeutics Inc
11/05/20243:05PMGlobeNewswire Inc.Mineralys Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:MLYSMineralys Therapeutics Inc
10/30/20247:03AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLYSMineralys Therapeutics Inc
10/30/20247:00AMGlobeNewswire Inc.Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of HypertensionNASDAQ:MLYSMineralys Therapeutics Inc
10/22/20247:00AMGlobeNewswire Inc.Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024NASDAQ:MLYSMineralys Therapeutics Inc
09/25/20247:06AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLYSMineralys Therapeutics Inc
09/25/20247:00AMGlobeNewswire Inc.Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of HypertensionNASDAQ:MLYSMineralys Therapeutics Inc
08/13/20243:10PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MLYSMineralys Therapeutics Inc
08/13/20243:07PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLYSMineralys Therapeutics Inc
08/13/20243:05PMGlobeNewswire Inc.Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:MLYSMineralys Therapeutics Inc
08/05/20243:05PMGlobeNewswire Inc.Mineralys Therapeutics to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024NASDAQ:MLYSMineralys Therapeutics Inc
06/17/20243:33PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MLYSMineralys Therapeutics Inc
06/17/20243:31PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:MLYSMineralys Therapeutics Inc
06/14/20247:06AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLYSMineralys Therapeutics Inc
06/14/20247:00AMGlobeNewswire Inc.Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of DirectorsNASDAQ:MLYSMineralys Therapeutics Inc
06/10/20243:02PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLYSMineralys Therapeutics Inc
05/31/20243:06PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLYSMineralys Therapeutics Inc
05/23/20243:20PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MLYSMineralys Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:MLYS